Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer

Cancer Detection and Prevention

Volumn 32, Issue 2, 2008, Pages 144-148

  Nowacka Zawisza, Maria ^a   Bryś, Magdalena ^a   Romanowicz Makowska, Hanna ^b   Kulig, Andrzej ^b   Krajewska, Wanda M ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

BRCA2; Breast cancer; Clinicopathological parameters; Heterozygous alleles; Loss of heterozygosity (LOH); Microsatelite markers; RAD51

Indexed keywords

BRCA2 PROTEIN; RAD51 PROTEIN; STEROID RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CHROMOSOME 13Q; CHROMOSOME 15Q; CLINICAL ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; GENE AMPLIFICATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA2; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RAD51 RECOMBINASE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 47749121373     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2008.06.005     Document Type: Article

References (40)

1. Ingvarsson S. Molecular genetics of breast cancer progression. Semin Cancer Biol 9 (1999) 277-288
2. Kollias J., Man S., Marafie M., Carpenter K., Pinder S., Ellis I.O., et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat 64 (2000) 241-251
3. Wooster R., Neuhausen S.L., Mangion J., Quirk Y., Ford D., Collins N., et al. Localization of breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (1994) 2088-2090
4. Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12 (1996) 333-337
5. Bork P., Blomberg N., and Nilges M. Internal repeats in the BRCA2 protein sequence. Nat Genet 13 (1996) 22-23
6. Wong A.K., Pero R., Ormonde P.A., Tavtigian S.V., and Bartel P.L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272 (1997) 31941-31944
7. Chen P.L., Chen C.F., Chen Y., Xiao J., Sharp Z.D., and Lee W.H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 95 (1998) 5287-5292
8. Yang H., Li Q., Fan J., Holloman W.K., and Pavletich N.P. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature 433 (2005) 653-657
9. Turner N., Tutt A., and Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5 (2005) 388-393
10. Wright D.K., and Manson M.M. Sample preparation from paraffin-embedded tissues. In: Innis M.A. (Ed). PCR protocols: a guide to methods and application (1990), Academic Press, Inc., San Diego 153-156
11. Rolfs A., Schuller I., Finckh U., and Weber-Rolfs J. PCR: clinical diagnostic and research (1992), Springer Lab p. 81-4
12. The GDB Human Genome Database, the official world-wide database for the annotation of the Human Genome [database on Internet]. Research Triangle Park (NC): Research Triangle Institute International; c2007-[cited February 2, 2007]. [Available from: http://www.gdb.org].
13. Cawkwell L., Bell S.M., Lewis F.A., Dixon M.F., Taylor G.R., and Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 67 (1993) 1262-1267
14. Miyakis S., and Spandidos D.A. Allelic loss in breast cancer. Cancer Detect Prev 26 (2002) 426-434
15. Wick W., Petersen I., Schmutzler R.K., Wolfarth B., Lenartz D., Bierhoff E., et al. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 12 (1996) 973-978
16. Gonzalez R., Silva J.M., Dominguez G., Garcia J.M., Martinez G., Vargas J., et al. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Br J Cancer 81 (1999) 503-509
17. Shen C.Y., Yu J.C., Lo Y.L., Kuo C.H., Yue C.T., Jou Y.S., et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60 (2000) 3884-3892
18. Balsara B.R., Bell D.W., Sonoda G., De Rienzo A., du Manoir S., Jhanwar S.C., et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 59 (1999) 450-454
19. De Rienzo A., Balsara B.R., Apostolou S., Jhanwar S.C., and Testa J.R. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene 20 (2001) 6245-6249
20. Natrajan R., Louhelainen J., Williams S., Laye J., and Knowles M.A. High-resolution deletion mapping of 15q13.2-q21. 1 in transitional cell carcinoma of the bladder. Cancer Res 63 (2003) 7657-7662
21. Cleton-Jansen A.M., Collins N., Lakhani S.R., Weissenbach J., Devilee P., Cornelisse C.J., et al. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 72 (1995) 1241-1244
22. van den Berg J., Johannsson O., Hakansson S., Olsson H., and Borg A. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. Br J Cancer 74 (1996) 1615-1619
23. Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13 (1996) 238-240
24. Teng D.H., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S., et al. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13 (1996) 241-244
25. Eiriksdottir G., Johannesdottir G., Ingvarsson S., Bjornsdottir I.B., Jonasson J.G., Agnarsson B.A., et al. Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer 34 (1998) 2076-2081
26. Silva J.M., Gonzalez R., Provencio M., Dominguez G., Garcia J.M., Gallego I., et al. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res Treat 53 (1999) 9-17
27. Katsama A., Sourvinos G., Zachos G., and Spandidos D.A. Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett 150 (2000) 165-170
28. Foster K.A., Harrington P., Kerr J., Russell P., DiCioccio R.A., Scott I.V., et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56 (1996) 3622-3625
29. Takahashi H., Chiu H.C., Bandera C.A., Behbakht K., Liu P.C., Couch F.J., et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56 (1996) 2738-2741
30. Prechtel D., Werenskiold A.K., Prechtel K., Keller G., and Hofler H. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer. Diagn Mol Pathol 7 (1998) 57-62
31. Kwiatkowska E., Teresiak M., Breborowicz D., and Mackiewicz A. Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer 98 6 (2002) 943-945
32. Charef-Hamza S., Trimeche M., Ziadi S., Amara K., Gaddas N., Mokni M., et al. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer. Cancer Lett 224 2 (2005) 185-191
33. Santos S.C., Cavalli L.R., Cavalli I.J., Lima R.S., Haddad B.R., and Ribeiro E.M. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil. J Clin Pathol 57 4 (2004) 374-377
34. Huang B., Starostik P., Kühl J., Tonn J.C., and Roggendorf W. Loss of heterozygosity on chromosome 22 in human ependymomas. Acta Neuropathol 103 4 (2002) 415-420
35. Levy-Lahad E., Lahad A., Eisenberg S., Dagan E., Paperna T., Kasinetz L., et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98 (2001) 3232-3236
36. Wang W.W., Spurdle A.B., Kolachana P., Bove B., Modan B., Ebbers S.M., et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 10 (2001) 955-960
37. Błasiak J., Przybyłowska K., Czechowska A., Zadrożny M., Pertyński T., Rykała J., et al. Analysis of the G/C polymorphism in the 5'-untranslated region of the RAD51 gene in breast cancer. Acta Biochim Pol 50 (2003) 249-253
38. Kadouri L., Kote-Jarai Z., Hubert A., Durocher F., Abeliovich D., Glaser B., et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 90 10 (2004) 2002-2005
39. Romanowicz-Makowska H., Smolarz B., and Kulig A. Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer. Pol J Pathol 56 (2005) 161-165
40. Śliwiński T., Krupa R., Majsterek I., Rykala J., Kołacińska A., Morawiec Z., et al. Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast Cancer Res Treat 94 (2005) 105-109